证券研究报告 | 公司研究 gszqdatemark 2025 05 22 年 月 日 阳光诺和（688621.SH） 收购朗研加码创新，"研发服务+管线培育+新质产业链"三位一体 拟收购朗研 100%股权，助力创新转型加速。公司拟通过发行股份及可转 换公司债券方式购买江苏朗研生命科技控股有限公司 100%股权，并向不 超过 35 名特定投资者发行股份募集配套资金。收购朗研生命有望提高行 业竞争力和盈利能力，完善战略布局，一方面，公司能够实现自主研发产 品的孵化和实施，充分发挥公司研发优势和朗研生命的生产销售优势，促 进研发品种落地以及朗研生命产能释放，形成公司新的盈利增长点。另一 方面，公司将增加医药工业板块业务，实现"CRO+创新研发+医药工业" 的产业布局。未来，医药工业板块将成为公司主营业务的重要组成部分， 进一步提高上市公司盈利能力及抗风险能力，促进上市公司的可持续发 展。 发布股权激励草案，深度绑定核心骨干。公司本次激励计划拟授予的限制 性股票 272.1783 万股，占本激励计划草案公告时公司股本总额 11,200 万 股的 2.43%，授予价格为 22.78 元/股，激励对象 127 人，包括 ...

证券研究报告 | 行业点评 gszqdatemark 2025 05 22 年 月 日 商贸零售 4 月社零同比增长 5.1%，基本符合预期 4 月社零同比增长 5.1%，基本符合预期。据国家统计局及 Wind 数据， 2025 年 4 月份社会消费品零售总额为 37174 亿元/同比+5.1%，增速环比 为-0.8pct；其中除汽车以外的消费品零售额 33548 亿元/同比+5.6%，排 除石油及汽车因素以外的消费品零售额 31684 亿元/同比+4.8%。价上来 看，4 月 CPI 为同比-0.1%。整体而言，2025 年 1-4 月社会消费品零售总 额 161845 亿元/同比+4.7%，除汽车以外的消费品零售额 147005 亿元/ 同比+5.2%，基本符合预期。 分品类看，必选品类同比均实现增长，文化办公用品环比增长加速。其 中：1）必选品类：同比均保持正增。4 月粮油食品/饮料/烟酒/日用品分 别同比+14.0%/+2.9%/+4.0%/+7.6%，环比+0.2pct/-1.5pct/-4.5pct/- 1.2pct；2）可选：仅石油制品同比下滑，文化办公用品/金银珠宝增长环 比大幅加速。4 月家 ...

Investment Rating - The industry maintains a rating of "Increase" [5] Core Viewpoints - The retail sector shows a stable recovery in 2025, with some sub-sectors improving marginally, supported by policy stimuli, indicating positive future expectations [4][31] - In April 2025, the total retail sales of consumer goods reached 37,174 billion yuan, with a year-on-year growth of 5.1%, aligning with expectations [1][8] - The consumer price index (CPI) in April 2025 was -0.1% year-on-year, indicating deflationary pressures [2][11] Summary by Sections Retail Sales Performance - In April 2025, retail sales excluding automobiles reached 33,548 billion yuan, with a year-on-year increase of 5.6% [1][8] - The total retail sales from January to April 2025 amounted to 161,845 billion yuan, reflecting a year-on-year growth of 4.7% [1][8] Category Analysis - Essential categories showed positive growth in April 2025, with food and oil products increasing by 14.0% and 2.9% respectively [2][13] - Optional categories saw varied performance, with home appliances growing by 38.8% and cultural office supplies by 33.5% [2][13] Regional and Channel Insights - Urban retail sales in April 2025 were 32,376 billion yuan, up 5.2% year-on-year, while rural retail sales were 4,798 billion yuan, up 4.7% [3][25] - Online retail sales for physical goods reached 39,265 billion yuan from January to April 2025, representing a year-on-year increase of 5.8% and accounting for 24.3% of total retail sales [3][25] Investment Recommendations - The report suggests potential investment opportunities in hospitality and tourism sectors, highlighting companies such as Huazhu Group and Xiangyuan Cultural Tourism [4][31] - The ongoing adjustment in retail strategies is expected to benefit companies like Yonghui Supermarket and Chongqing Department Store [4][31]

Group 1: Macro Analysis - The report analyzes the risk of a sell-off in US Treasury bonds, indicating that the scale of US Treasury holdings and daily trading volume is significantly larger than that of any other country, suggesting that no single nation can manipulate the US Treasury market [2] - Historical data shows that reductions in overseas holdings have less impact on US Treasury trends compared to fundamental variables, but a coordinated sell-off by multiple countries in response to tariffs could significantly disrupt the US Treasury market and global financial markets [2] Group 2: Fixed Income - In April, the broad fiscal revenue showed a slight positive change with a year-on-year increase of 2.7%, while fiscal expenditure grew by 12.9% year-on-year, indicating an acceleration in spending [2] - Cumulatively, from January to April, broad fiscal revenue decreased by 1.3% year-on-year, while broad fiscal expenditure increased by 7.2% [2] Group 3: Food and Beverage Industry - Investment recommendations for the liquor sector emphasize strengthening core capabilities and highlight three main lines: leading brands with increasing market share, high-certainty regional brands, and resilient recovery stocks [3] - For consumer products, the report suggests focusing on opportunities in beer and beverages, with a particular emphasis on companies benefiting from policy changes or recovery improvements, as well as those with high growth potential [3] Group 4: Pharmaceutical Industry - The report discusses the collaboration between Sanofi and Pfizer regarding the PD-1/VEGF bispecific antibody SSGJ-707, which includes a non-refundable upfront payment of $1.25 billion and potential milestone payments up to $4.8 billion [6] - Sanofi retains rights for development and commercialization in mainland China, while Pfizer will have an option for commercialization in that region based on agreed financial terms [6]

Report Industry Investment Rating No relevant information provided. Core Viewpoints of the Report - In April, the broad fiscal revenue turned slightly positive, and the intensity of fiscal expenditure continued to increase. Looking ahead, both domestic and external demands are under pressure due to the fluctuating tariff policies, so incremental fiscal policies are still worth expecting [1][4]. Summary by Relevant Catalogs Revenue Side - In April, the year - to - date tax revenue growth rate turned positive for the first time, the non - tax revenue growth rate declined, and the general budget revenue growth rate slightly increased. From January to April, the central general public budget revenue decreased by 3.8% year - on - year, while the local general public budget revenue increased by 2.2% year - on - year [1][10]. - In terms of taxes, personal income tax and enterprise income tax had relatively high growth rates. New - quality productivity supported tax growth. The government - funded revenue growth rate turned positive for the first time in nearly a year, which may be related to the improvement in land transactions at the beginning of the year and the lag in land transfer revenues, but its sustainability remains to be seen [2][12]. Expenditure Side - In April, the expenditure of the general public budget maintained a relatively high growth rate, and the expenditure growth rate of government - funded funds further increased, indicating that fiscal expenditure was front - loaded. Structurally, the expenditure on social sciences, culture, and education increased significantly [3][16]. - Measured by the broad deficit, fiscal efforts were intensified and were earlier than in previous years. As of April, the cumulative broad fiscal deficit was 2.65 trillion yuan, and the current cumulative broad deficit rate was 1.9%, higher than the same period from 2021 - 2024 and similar to that in 2020 [4][22].

证券研究报告 | 宏观研究 gszqdatemark 2025 05 21 年 月 日 宏观点评 三大维度看，美债抛售风险有多大？ 4 月初特朗普宣布对等关税后，部分观点认为海外国家可以采取抛售美债 的方式来反制，虽然近期关税有所缓和，但尚不能排除后续是否出现反复。 由于目前美债规模十分庞大，市场担忧一旦海外国家抛售美债，可能导致 美债市场出现系统性风险。本文从美债期限结构与投资者结构、到期分布 与偿还压力、交易规模与外国减持复盘这 3 大维度，详细分析了美债市场 的运行状况，并对潜在抛售风险做出评估。 核心结论：美债存量规模和日均交易规模均十分庞大，远超任一海外国家 持有美债的规模，因此单一国家不具备操控美债市场的能力。历史经验也 表明，海外国家减持对美债走势的影响要弱于基本面变量。需要警惕的是， 若关税反复引发"众怒"，促使海外各国实施联合抛售，则对美债市场乃至 全球金融市场造成的冲击将明显加剧。 1、美债期限结构与投资者结构 1、《关税下降对美国经济和通胀的影响——兼评美国 4 月 CPI 》 2025-05-14 2、《唯一确定的是不确定性——美联储 5 月议息会议 点评》 2025-05-08 3、 ...

Investment Rating - Investment recommendation: 1) Baijiu: Strengthen internal capabilities, accumulate power for improvement, medium to long-term allocation value highlighted, focus on "advantageous leaders, continued dividends, strong recovery" [3][4][19] Core Viewpoints - The Baijiu industry is characterized by "demand bottoming out, channel destocking, and stable wholesale prices" in 2025. Demand structure continues to differentiate, with better performance in mass price segments and some single products upgrading [4][17] - The beer and beverage sectors are expected to see a peak season, with a focus on alpha opportunities. The beer industry is transitioning from expectations to data verification, with positive growth anticipated in 2025 due to favorable weather, improved consumer confidence, and policy stimulation [4][25] - The consumer goods sector is experiencing a joint catalyst from product and channel innovations, with significant opportunities for iteration and innovation. The demand for health-conscious and cost-effective products is driving the expansion of the food industry [5][69] Summary by Sections Baijiu - The industry is experiencing a slowdown in growth, with companies focusing on long-term healthy growth. The demand is stabilizing, and leading companies are enhancing channel management to stabilize prices [4][13] - Major companies like Guizhou Moutai and Wuliangye are setting conservative growth targets, emphasizing quality development and shareholder returns [18][19] Beer & Beverages - The beer sector is entering a peak season with low comparative bases, and there are expectations for positive sales growth driven by improved conditions [25][30] - The functional beverage market is expanding, with leading companies like Dongpeng Beverage showing significant growth rates [48][52] Consumer Goods - The food industry is witnessing rapid innovation driven by both supply and demand, with a focus on health and convenience. The demand for healthy ingredients is leading to the emergence of new product categories [69][73] - The channel landscape is evolving, with discount formats and supermarkets adapting to meet consumer needs, leading to the rapid expansion of specialized stores and e-commerce [79][80]

证券研究报告 | 公司点评 gszqdatemark 2025 05 21 年 月 日 三生制药（01530.HK） 授权辉瑞 PD-1/VEGF 双抗，创新管线未来可期 公司发布公告：与辉瑞就 PD-1/VEGF 双抗 SSGJ-707 达成授权协议。 5 月 20 日，公司宣布，公司及附属子公司沈阳三生、三生国健与辉瑞签署 协议，将向辉瑞独家授予公司自主研发的突破性 PD-1/VEGF 双特异性抗 体 SSGJ-707 在全球（不包括中国内地）的开发、生产、商业化权利。公 司及沈阳三生将保留 SSGJ-707 在中国内地的开发、生产、商业化权利， 并基于届时商定的财务条款授予辉瑞对 SSGJ-707 在中国内地开展商业化 的选择权。根据协议，三生制药将获得 12.5 亿美元不可退还且不可抵扣 的首付款，以及最高可达 48 亿美元的开发、监管批准和销售里程碑付款。 公司还将根据授权地区的产品销售额收取两位数百分比的梯度销售分成。 此外，辉瑞将于协议生效日认购三生制药价值 1 亿美元的普通股股份。 SSGJ-707 临床效果获国际认可，财务回报助力公司研发体系升级。SSGJ- 707 是三生制药基于 CLF2 ...

证券研究报告 | 朝闻国盛 gszqdatemark 2025 05 21 年 月 日 朝闻国盛 2024 开发房企年报综述：行业全面亏损，头部房企依然具备显 著竞争优势 今日概览 ◼ 重磅研报 【宏观】4 月财政有喜有忧，年内大概率会扩赤字——20250520 【固定收益】存贷款利率再调降，影响几何？——20250520 【纺织服饰】新消费趋势下，如何寻找服饰板块投资机会？—— 20250520 【煤炭】有效供应环降，需求望迎改善，煤炭终迎年初至今配置良机— —20250520 【钢铁】4 月数据跟踪：粗钢产量同比持平，需求预期有望改善—— 20250520 【家用电器】倍轻松（688793.SH）-24 年盈利水平转正，海外增速更快 ——20250520 | 作者 | | --- | 分析师 夏君 执业证书编号：S0680519100004 邮箱：xiajun@gszq.com | 行业表现前五名 | | | | | --- | --- | --- | --- | | 行业 | 1 月 | 3 月 | 1 年 | | 美容护理 | 13.0% | 18.1% | 5.4% | | 汽车 | 8.9% | ...

证券研究报告 | 公司点评 gszqdatemark 2025 05 21 年 月 日 三生制药（01530.HK） 授权辉瑞 PD-1/VEGF 双抗，创新管线未来可期 公司发布公告：与辉瑞就 PD-1/VEGF 双抗 SSGJ-707 达成授权协议。 5 月 20 日，公司宣布，公司及附属子公司沈阳三生、三生国健与辉瑞签署 协议，将向辉瑞独家授予公司自主研发的突破性 PD-1/VEGF 双特异性抗 体 SSGJ-707 在全球（不包括中国内地）的开发、生产、商业化权利。公 司及沈阳三生将保留 SSGJ-707 在中国内地的开发、生产、商业化权利， 并基于届时商定的财务条款授予辉瑞对 SSGJ-707 在中国内地开展商业化 的选择权。根据协议，三生制药将获得 12.5 亿美元不可退还且不可抵扣 的首付款，以及最高可达 48 亿美元的开发、监管批准和销售里程碑付款。 公司还将根据授权地区的产品销售额收取两位数百分比的梯度销售分成。 此外，辉瑞将于协议生效日认购三生制药价值 1 亿美元的普通股股份。 SSGJ-707 临床效果获国际认可，财务回报助力公司研发体系升级。SSGJ- 707 是三生制药基于 CLF2 ...